MA32786B1 - Procede de traitement et de prevention de la thrombose utilisant l'etexilate de dabigatran ou un sel de celui-ci avec un profil de securite ameliore par rapport a la therapie de la warfarine classique - Google Patents

Procede de traitement et de prevention de la thrombose utilisant l'etexilate de dabigatran ou un sel de celui-ci avec un profil de securite ameliore par rapport a la therapie de la warfarine classique

Info

Publication number
MA32786B1
MA32786B1 MA33834A MA33834A MA32786B1 MA 32786 B1 MA32786 B1 MA 32786B1 MA 33834 A MA33834 A MA 33834A MA 33834 A MA33834 A MA 33834A MA 32786 B1 MA32786 B1 MA 32786B1
Authority
MA
Morocco
Prior art keywords
classic
salt
treating
relation
improved safety
Prior art date
Application number
MA33834A
Other languages
Arabic (ar)
English (en)
Inventor
Paul A Reilly
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA32786B1 publication Critical patent/MA32786B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un procédé permettant de prévenir une attaque chez un patient souffrant de fibrillation auriculaire et présentant au moins un facteur de risque concernant des évènements de saignement majeurs. Le procédé consiste à lui administrer 110 mg b.i.d. D'étexilate de dabigatran, éventuellement sous la forme d'un sel de celui-ci pharmaceutiquement acceptable.
MA33834A 2008-11-11 2011-05-11 Procede de traitement et de prevention de la thrombose utilisant l'etexilate de dabigatran ou un sel de celui-ci avec un profil de securite ameliore par rapport a la therapie de la warfarine classique MA32786B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11340408P 2008-11-11 2008-11-11
US23755209P 2009-08-27 2009-08-27
PCT/EP2009/064873 WO2010055021A1 (fr) 2008-11-11 2009-11-10 Procede de traitement et de prevention de la thrombose utilisant l'etexilate de dabigatran ou un sel de celui-ci avec un profil de securite ameliore par rapport a la therapie de la warfarine classique

Publications (1)

Publication Number Publication Date
MA32786B1 true MA32786B1 (fr) 2011-11-01

Family

ID=41463076

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33834A MA32786B1 (fr) 2008-11-11 2011-05-11 Procede de traitement et de prevention de la thrombose utilisant l'etexilate de dabigatran ou un sel de celui-ci avec un profil de securite ameliore par rapport a la therapie de la warfarine classique

Country Status (21)

Country Link
US (3) US8962574B2 (fr)
EP (1) EP2358368A1 (fr)
JP (1) JP2013510072A (fr)
KR (1) KR20110086700A (fr)
CN (2) CN103356614A (fr)
AR (1) AR074313A1 (fr)
AU (1) AU2009315729A1 (fr)
BR (1) BRPI0921479A2 (fr)
CA (1) CA2738883A1 (fr)
CL (1) CL2011000798A1 (fr)
CO (1) CO6361938A2 (fr)
EA (1) EA201100756A1 (fr)
EC (1) ECSP11011030A (fr)
IL (1) IL211852A0 (fr)
MA (1) MA32786B1 (fr)
MX (1) MX2011004614A (fr)
NZ (1) NZ592616A (fr)
PE (1) PE20110431A1 (fr)
TN (1) TN2011000228A1 (fr)
TW (1) TW201022237A (fr)
WO (1) WO2010055021A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510072A (ja) 2008-11-11 2013-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 従来のワルファリン治療に対して安全性プロフィールが改善されたダビガトランエテキシレートまたはその塩を使用して血栓症を治療または予防するための方法
WO2012122024A2 (fr) * 2011-03-04 2012-09-13 Russell Medford Procédé de criblage pour identifier des patients à risque de lésion hépatique induite par médicament
EA201400737A1 (ru) * 2011-12-22 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
WO2014001220A1 (fr) 2012-06-25 2014-01-03 Boehringer Ingelheim International Gmbh Procédé de prévention d'un accident vasculaire cérébral
WO2014060545A1 (fr) * 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Compositions pharmaceutiques de dabigatran sous forme de base libre
WO2014060561A1 (fr) * 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations pharmaceutiques orales contenant du dabigatran
CN103788063B (zh) * 2012-10-29 2016-01-20 天津药物研究院 四水合达比加群酯晶体及其制备方法和药物用途
IN2013CH05441A (fr) * 2013-11-26 2015-05-29 Aurobindo Pharma Ltd
CN104291789B (zh) * 2014-09-28 2016-03-02 定远县绿苑新型建材有限公司 一种吸水性强的多孔砖及其制备方法
CN105560236B (zh) * 2014-10-30 2019-03-15 成都百裕制药股份有限公司 一种含有银杏内酯b和非肽类凝血酶抑制剂的药物组合物及其制备方法和用途
CN108133754B (zh) * 2017-12-19 2019-03-12 中国医学科学院阜外医院 一种溶栓后出血风险的预测系统
CN110339193B (zh) 2018-04-04 2022-04-29 上海汉都医药科技有限公司 含达比加群酯的药物组合物及其制备方法
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
CN111983085B (zh) * 2020-08-21 2022-05-31 江苏省食品药品监督检验研究院 一组血清代谢标志物在预测华法林个体药效和指导华法林个体化用药中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US4145308A (en) 1977-07-07 1979-03-20 General Electric Company Anti-foam silicone emulsion, and preparation and use thereof
US4191741A (en) 1978-09-22 1980-03-04 Eli Lilly And Company Removable drug implant
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
US5277820A (en) 1992-02-06 1994-01-11 Hemocleanse, Inc. Device and method for extracorporeal blood treatment
EP1078917A4 (fr) 1998-02-17 2002-11-06 Ono Pharmaceutical Co Derives amidino utilises comme ingredients actifs et medicaments les contenant
GB0003782D0 (en) 2000-02-17 2000-04-05 Dumex Ltd As Process
US6620439B1 (en) 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
US6555581B1 (en) * 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
EP1807086A1 (fr) 2004-10-25 2007-07-18 Boehringer Ingelheim International GmbH Utilisation de dipyridamole en association avec des antithrombotiques pour traiter et prevenir des maladies thromboemboliques
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005020002A1 (de) 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
US20070079972A1 (en) 2005-09-23 2007-04-12 Fireaway Llc Manually activated, portable fire-extinguishing aerosol generator
DE102005061623A1 (de) 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
DE102005061624A1 (de) 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen
CA2657270A1 (fr) 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh Nouvelles indications pediatriques pour des inhibiteurs directs de la thrombine
CA2657269A1 (fr) 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh Nouvelles indications portant sur les inhibiteurs directs de la thrombine
JP2009543842A (ja) * 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓血管分野における直接トロンビン阻害薬のための新規適応
US20100087488A1 (en) 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
DE102006054005A1 (de) 2006-11-16 2008-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
EP1956018A1 (fr) 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Procédé de préparation d'un dérivé du benzimidazole
RU2010143901A (ru) 2008-03-28 2012-05-10 Бёрингер Ингельхайм Интернациональ Гмбх (De) Способ получения композиций дабигатрана для перорального введения
WO2009118321A1 (fr) 2008-03-28 2009-10-01 Boehringer Ingelheim International Gmbh Procédé de production de granules d'acide
AU2009259440B2 (en) 2008-06-16 2014-05-29 Boehringer Ingelheim International Gmbh Method for producing an intermediate product of dabigatran etexilate
EP2300431B1 (fr) 2008-06-16 2016-01-06 Boehringer Ingelheim International GmbH Procédé de fabrication d'un produit intermédiaire dans la synthèse de dabigatran
NZ589746A (en) 2008-07-14 2012-10-26 Boehringer Ingelheim Int Method for manufacturing medicinal compounds containing dabigatran
BRPI0917507A2 (pt) 2008-08-19 2015-11-17 Boehring Ingelheim Internat Gmbh dabigatrana para a caterização cardíaca percutânea intervencionista
EP2328581A1 (fr) 2008-08-19 2011-06-08 Boehringer Ingelheim International GmbH Utilisation du dabigatran-étexilate pour le traitement de patients souffrant d hypertension pulmonaire
CA2734809A1 (fr) 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Dabigatran utilise pour le traitement de tumeurs
KR20110082563A (ko) 2008-11-11 2011-07-19 베링거 인겔하임 인터내셔날 게엠베하 통상의 와파린 요법에 비해 효능이 향상된 다비가트란 에텍실레이트 또는 이의 염을 사용하여 혈전증을 치료하거나 예방하는 방법
JP2013510072A (ja) 2008-11-11 2013-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 従来のワルファリン治療に対して安全性プロフィールが改善されたダビガトランエテキシレートまたはその塩を使用して血栓症を治療または予防するための方法
NZ592615A (en) 2008-11-11 2013-06-28 Boehringer Ingelheim Int Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
AU2010209804B2 (en) 2009-02-02 2015-07-16 Boehringer Ingelheim International Gmbh Lyophilised dabigatran
US8399678B2 (en) 2009-11-18 2013-03-19 Boehringer Ingelheim International Gmbh Process for the manufacture of dabigatran etexilate

Also Published As

Publication number Publication date
NZ592616A (en) 2013-04-26
BRPI0921479A2 (pt) 2016-01-12
PE20110431A1 (es) 2011-07-13
TW201022237A (en) 2010-06-16
US8962574B2 (en) 2015-02-24
US20110269703A1 (en) 2011-11-03
WO2010055021A1 (fr) 2010-05-20
AU2009315729A1 (en) 2010-05-20
US20100322869A1 (en) 2010-12-23
CL2011000798A1 (es) 2012-01-27
ECSP11011030A (es) 2011-07-29
JP2013510072A (ja) 2013-03-21
CO6361938A2 (es) 2012-01-20
EP2358368A1 (fr) 2011-08-24
MX2011004614A (es) 2011-05-31
CN103356614A (zh) 2013-10-23
CA2738883A1 (fr) 2010-05-20
KR20110086700A (ko) 2011-07-29
US20120282187A1 (en) 2012-11-08
EA201100756A1 (ru) 2011-12-30
CN102209544A (zh) 2011-10-05
AR074313A1 (es) 2011-01-05
IL211852A0 (en) 2011-06-30
TN2011000228A1 (en) 2012-12-17

Similar Documents

Publication Publication Date Title
MA32786B1 (fr) Procede de traitement et de prevention de la thrombose utilisant l'etexilate de dabigatran ou un sel de celui-ci avec un profil de securite ameliore par rapport a la therapie de la warfarine classique
MA32785B1 (fr) Procede de traitement ou de prevention de thrombose a l'aide d'etexilate de dabigatran ou d'un sel de celui-ci avec une efficacite accrue par rapport a une therapie classique par warfarine
WO2005049084A3 (fr) Inhibition de canaux trp comme traitement contre l'hypertrophie et l'insuffisance cardiaques
NO20056252L (no) Terapeutiske og profylaktiske metoder for neuromuskulaere lidelser
EA200400825A1 (ru) Способы замедления старения, а также лечения и профилактики заболеваний, связанных со старением
WO2006040688A3 (fr) Procede pour traiter des maladies de peau
HK1120409A1 (en) Treatment of diseases by subcutaneous administration of a vegf antagonist
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
WO2006098603A3 (fr) Composition renfermant de l'isoorientine pour suppression d'histamine
SG156681A1 (en) Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
DE602007004849D1 (de) Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie
EA201101231A1 (ru) Способы предотвращения или снижения риска смертности
WO2008086452A3 (fr) Traitement et prévention de la maladie d'alzheimer
NZ592613A (en) Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
HK1099918A1 (en) Composition and use for prevention or treatment of stomatitis
WO2006053014A3 (fr) Inhibition selective de rock1 dans une therapie cardiaque
WO2004043345A3 (fr) Extrait de trapa natans et ses methodes d'utilisation
WO2008016665A3 (fr) Composés et méthodes de traitement de troubles médiés par flt3
MX2008009161A (es) Tratamiento de enfermedad cardiovascular en mexicano-americanos, usando nebivolol.
AU2019284008A1 (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
WO2004045505A3 (fr) Extrait de stephaniae sinica diels et ses methodes d'utilisation
Mansencal et al. Management of atrial fibrillation in heart failure in the elderly
UA105645C2 (uk) Застосування етексилату дабігатрану, необов'язково у формі фармацевтично прийнятної солі, для запобігання інсульту у пацієнта, що страждає від миготливої аритмії
WO2005097088A3 (fr) Inhibition de l'export nucleaire en tant que traitement de l'hypertrophie cardiaque et de l'insuffisance cardiaque
UA104158C2 (ru) Профилактика инсульта у пациента, который страдает мигающей аритмией, с использованием этексилата дабигатрана